{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:35:36Z","timestamp":1793655336253,"version":"4.5.1"},"reference-count":83,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2025,9,16]]},"abstract":"<jats:sec id=\"ab-jrv250024-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Prostatitis is defined as infection, inflammation, or pain of the prostate gland and affects approximately 9.3% of men in their lifetime.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv250024-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>\n                      Acute bacterial prostatitis consists of a urinary tract infection (UTI) that includes infection of the prostate, typically associated with fever or chills and caused by gram-negative bacteria, such as\n                      <jats:italic>Escherichia coli, Klebsiella,<\/jats:italic>\n                      or\n                      <jats:italic>Pseudomonas<\/jats:italic>\n                      , in 80% to 97% of cases. First-line therapy for acute prostatitis is broad-spectrum intravenous or oral antibiotics, such as intravenous piperacillin-tazobactam, ceftriaxone, or oral ciprofloxacin, which has a 92% to 97% success rate when prescribed for 2 to 4 weeks for people with febrile UTI and acute prostatitis. Chronic bacterial prostatitis is defined as a persistent bacterial infection of the prostate, typically presenting as recurrent UTIs from the same strain. Up to 74% of chronic bacterial prostatitis diagnoses are due to gram-negative organisms, such as\n                      <jats:italic>E coli<\/jats:italic>\n                      . First-line therapy for chronic bacterial prostatitis is a minimum 4-week course of levofloxacin or ciprofloxacin. Chronic prostatitis\/chronic pelvic pain syndrome (CP\/CPPS) presents as pelvic pain or discomfort for at least 3 months and is associated with urinary symptoms, such as urinary frequency. CP\/CPPS is diagnosed when evaluation, including history and physical examination, urine culture, and postvoid residual measurement, does not identify other causes for the symptoms, such as infection, cancer, urinary obstruction, or urinary retention. The National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) measures symptom severity (scale of 0-43), with a 6-point change considered clinically meaningful. First-line oral therapy for CP\/CPPS with urinary symptoms is \u03b1-blockers (eg, tamsulosin, alfuzosin; \u0394NIH-CPSI score difference vs placebo\u2009=\u2009\u221210.8 to \u22124.8). Other oral therapies are associated with modest changes in NIH-CPSI score compared with placebo, including anti-inflammatory drugs (eg, ibuprofen; \u0394NIH-CPSI score difference\u2009=\u2009\u22122.5 to \u22121.7), pregabalin (\u0394NIH-CPSI score difference\u2009=\u2009\u22122.4), and pollen extract (\u0394NIH-CPSI score difference\u2009=\u2009\u22122.49).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv250024-3\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>Prostatitis includes acute bacterial prostatitis, chronic bacterial prostatitis, and CP\/CPPS, each of which is diagnosed and treated differently. First-line treatments are broad-spectrum antibiotics for acute bacterial prostatitis (such as piperacillin-tazobactam, ceftriaxone, or ciprofloxacin), at least 4 weeks of fluoroquinolones for chronic bacterial prostatitis, and \u03b1-blockers for CP\/CPPS with urinary symptoms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jama.2025.11499","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T15:00:23Z","timestamp":1754924423000},"page":"1003","source":"Crossref","is-referenced-by-count":45,"title":["Prostatitis"],"prefix":"10.1001","volume":"334","author":[{"given":"Benjamin J.","family":"Borgert","sequence":"first","affiliation":[{"name":"Department of Urology, University of North Carolina School of Medicine, Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"Wallen","sequence":"additional","affiliation":[{"name":"Department of Urology, Medical University of South Carolina, Charleston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minh N.","family":"Pham","sequence":"additional","affiliation":[{"name":"Department of Urology, University of North Carolina School of Medicine, Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"jrv250024r2","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1001\/jama.282.3.236","article-title":"NIH consensus definition and classification of prostatitis.","volume":"282","author":"Krieger","year":"1999","journal-title":"JAMA"},{"key":"jrv250024r3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1471-2334-8-12","article-title":"Acute bacterial prostatitis: heterogeneity in diagnostic criteria and management: retrospective multicentric analysis of 371 patients diagnosed with acute prostatitis.","volume":"8","author":"Etienne","year":"2008","journal-title":"BMC Infect Dis"},{"issue":"1","key":"jrv250024r4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00345-005-0040-4","article-title":"Acute bacterial prostatitis: two different sub-categories according to a previous manipulation of the lower urinary tract.","volume":"24","author":"Mill\u00e1n-Rodr\u00edguez","year":"2006","journal-title":"World J Urol"},{"issue":"4","key":"jrv250024r5","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S0090-4295(98)00034-X","article-title":"Prevalence of a physician-assigned diagnosis of prostatitis: the Olmsted County Study of Urinary Symptoms and Health Status Among Men.","volume":"51","author":"Roberts","year":"1998","journal-title":"Urology"},{"issue":"1","key":"jrv250024r6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.idc.2013.10.005","article-title":"Management of non\u2013catheter-associated complicated urinary tract infection.","volume":"28","author":"Dielubanza","year":"2014","journal-title":"Infect Dis Clin North Am"},{"key":"jrv250024r7","doi-asserted-by":"publisher","first-page":"S96","DOI":"10.1016\/j.ijantimicag.2007.07.041","article-title":"Acute bacterial prostatitis in Korea: clinical outcome, including symptoms, management, microbiology and course of disease.","volume":"31","author":"Ha","year":"2008","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"jrv250024r8","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.jiac.2015.01.014","article-title":"Clinical and microbiological characteristics of spontaneous acute prostatitis and transrectal prostate biopsy\u2013related acute prostatitis: is transrectal prostate biopsy\u2013related acute prostatitis a distinct acute prostatitis category?","volume":"21","author":"Kim","year":"2015","journal-title":"J Infect Chemother"},{"issue":"6","key":"jrv250024r9","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1086\/528873","article-title":"Performance of the urine leukocyte esterase and nitrite dipstick test for the diagnosis of acute prostatitis.","volume":"46","author":"Etienne","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"8","key":"jrv250024r10","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.5957","article-title":"Association of timing of sexual partnerships and perceptions of partners\u2019 concurrency with reporting of sexually transmitted infection diagnosis.","volume":"1","author":"Mercer","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"5","key":"jrv250024r11","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1128\/JCM.00425-10","article-title":"Should blood cultures be performed for patients with acute prostatitis?","volume":"48","author":"Etienne","year":"2010","journal-title":"J Clin Microbiol"},{"issue":"1","key":"jrv250024r12","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12894-016-0153-7","article-title":"Acute bacterial prostatitis and abscess formation.","volume":"16","author":"Lee","year":"2016","journal-title":"BMC Urol"},{"issue":"4","key":"jrv250024r13","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/nrurol.2011.22","article-title":"The etiology and management of acute prostatitis.","volume":"8","author":"Brede","year":"2011","journal-title":"Nat Rev Urol"},{"issue":"11","key":"jrv250024r14","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.44495","article-title":"Guidelines for the prevention, diagnosis, and management of urinary tract infections in pediatrics and adults: a WikiGuidelines group consensus statement.","volume":"7","author":"Nelson","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"1","key":"jrv250024r15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.eururo.2024.03.035","article-title":"European Association of Urology guidelines on urological infections: summary of the 2024 guidelines.","volume":"86","author":"Kranz","year":"2024","journal-title":"Eur Urol"},{"issue":"2","key":"jrv250024r16","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.juro.2017.01.103","article-title":"An update of the American Urological Association white paper on the prevention and treatment of the more common complications related to prostate biopsy.","volume":"198","author":"Liss","year":"2017","journal-title":"J Urol"},{"issue":"10","key":"jrv250024r17","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1093\/cid\/cis194","article-title":"Escherichia coli bloodstream infection after transrectal ultrasound-guided prostate biopsy: implications of fluoroquinolone-resistant sequence type 131 as a major causative pathogen.","volume":"54","author":"Williamson","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"1","key":"jrv250024r18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1080\/0036554021000026988","article-title":"Ciprofloxacin for 2 or 4 weeks in the treatment of febrile urinary tract infection in men: a randomized trial with a 1 year follow-up.","volume":"35","author":"Ulleryd","year":"2003","journal-title":"Scand J Infect Dis"},{"issue":"7","key":"jrv250024r19","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.22281","article-title":"Urinary retention evaluation and catheterization algorithm for adult inpatients.","volume":"7","author":"Chrouser","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"6","key":"jrv250024r20","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/bju.15727","article-title":"Suprapubic catheterisation: a study of 1000 elective procedures.","volume":"129","author":"Hobbs","year":"2022","journal-title":"BJU Int"},{"issue":"3","key":"jrv250024r21","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/sj.sc.3100536","article-title":"Long-term suprapubic catheterisation: clinical outcome and satisfaction survey.","volume":"36","author":"Sheriff","year":"1998","journal-title":"Spinal Cord"},{"issue":"5","key":"jrv250024r22","first-page":"258","article-title":"The 2001 Giessen Cohort Study on patients with prostatitis syndrome\u2014an evaluation of inflammatory status and search for microorganisms 10 years after a first analysis.","volume":"35","author":"Schneider","year":"2003","journal-title":"Andrologia"},{"issue":"3","key":"jrv250024r23","doi-asserted-by":"publisher","first-page":"S119","DOI":"10.1007\/BF01643680","article-title":"Chronic prostatitis: a thorough search for etiologically involved microorganisms in 1,461 patients.","volume":"19","author":"Weidner","year":"1991","journal-title":"Infection"},{"issue":"4","key":"jrv250024r24","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/0090-4295(93)90584-W","article-title":"Diagnosis and treatment of 409 patients with prostatitis syndromes.","volume":"41","author":"de la Rosette","year":"1993","journal-title":"Urology"},{"issue":"12","key":"jrv250024r25","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/nrurol.2011.172","article-title":"Etiology and management of genitourinary tuberculosis.","volume":"8","author":"Abbara","year":"2011","journal-title":"Nat Rev Urol"},{"issue":"3","key":"jrv250024r26","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00345-013-1145-9","article-title":"The impact of biofilm-producing bacteria on chronic bacterial prostatitis treatment: results from a longitudinal cohort study.","volume":"32","author":"Bartoletti","year":"2014","journal-title":"World J Urol"},{"issue":"1","key":"jrv250024r27","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/j.1464-410X.1990.tb14864.x","article-title":"Pathogenesis of chronic bacterial prostatitis in an animal model.","volume":"66","author":"Nickel","year":"1990","journal-title":"Br J Urol"},{"issue":"3","key":"jrv250024r28","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1007\/s12275-011-0391-z","article-title":"Epidemiological features and resistance pattern in uropathogens isolated from chronic bacterial prostatitis.","volume":"49","author":"Cai","year":"2011","journal-title":"J Microbiol"},{"issue":"6","key":"jrv250024r29","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/j.1439-0272.2009.01033.x","article-title":"Eradication of Chlamydia trachomatis parallels symptom regression in chronic bacterial prostatitis patients treated with a fluoroquinolone-macrolide combination.","volume":"42","author":"Magri","year":"2010","journal-title":"Andrologia"},{"issue":"16","key":"jrv250024r30","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1056\/NEJMcp060423","article-title":"Clinical practice: chronic prostatitis and the chronic pelvic pain syndrome.","volume":"355","author":"Schaeffer","year":"2006","journal-title":"N Engl J Med"},{"issue":"4","key":"jrv250024r31","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s11934-996-0011-3","article-title":"The management of chronic prostatitis in men with HIV.","volume":"7","author":"Santillo","year":"2006","journal-title":"Curr Urol Rep"},{"issue":"5","key":"jrv250024r32","first-page":"492","article-title":"Bacteriologic localization patterns in bacterial prostatitis and urethritis.","volume":"5","author":"Meares","year":"1968","journal-title":"Invest Urol"},{"issue":"3","key":"jrv250024r33","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S0090-4295(99)00536-1","article-title":"Diagnosing and treating chronic prostatitis: do urologists use the four-glass test?","volume":"55","author":"McNaughton Collins","year":"2000","journal-title":"Urology"},{"key":"jrv250024r34","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000004564","article-title":"Male chronic pelvic pain: AUA guideline, part I: evaluation and management approach.","author":"Lai","journal-title":"J Urol"},{"issue":"6","key":"jrv250024r35","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1056\/NEJMcp1503950","article-title":"Clinical practice: urinary tract infections in older men.","volume":"374","author":"Schaeffer","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"jrv250024r36","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/0090-4295(85)90450-9","article-title":"Prostatitis, prostatosis, and prostatodynia.","volume":"25","author":"Orland","year":"1985","journal-title":"Urology"},{"issue":"1","key":"jrv250024r37","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S0022-5347(06)00498-8","article-title":"How does the pre-massage and post-massage 2-glass test compare to the Meares-Stamey 4-glass test in men with chronic prostatitis\/chronic pelvic pain syndrome?","volume":"176","author":"Nickel","year":"2006","journal-title":"J Urol"},{"issue":"4","key":"jrv250024r38","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/aja.2009.5","article-title":"Semen analysis in chronic bacterial prostatitis: diagnostic and therapeutic implications.","volume":"11","author":"Magri","year":"2009","journal-title":"Asian J Androl"},{"issue":"2","key":"jrv250024r39","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0022-5347(17)61919-0","article-title":"Chronic bacterial prostatitis and the diffusion of drugs into prostatic fluid.","volume":"103","author":"Stamey","year":"1970","journal-title":"J Urol"},{"issue":"1","key":"jrv250024r40","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.cmi.2022.05.035","article-title":"How I manage bacterial prostatitis.","volume":"29","author":"Lam","year":"2023","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"jrv250024r41","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/bju.13101","article-title":"Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis\/chronic pelvic pain syndrome: a consensus guideline.","volume":"116","author":"Rees","year":"2015","journal-title":"BJU Int"},{"issue":"6","key":"jrv250024r42","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1097\/01.ju.0000182152.28519.e7","article-title":"Incidence and clinical characteristics of National Institutes of Health type III prostatitis in the community.","volume":"174","author":"Clemens","year":"2005","journal-title":"J Urol"},{"issue":"6","key":"jrv250024r43","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1016\/S0022-5347(05)68090-1","article-title":"Prostate histopathology and the chronic prostatitis\/chronic pelvic pain syndrome: a prospective biopsy study.","volume":"162","author":"True","year":"1999","journal-title":"J Urol"},{"issue":"3","key":"jrv250024r44","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S0022-5347(05)64572-7","article-title":"Leukocyte and bacterial counts do not correlate with severity of symptoms in men with chronic prostatitis: the National Institutes of Health Chronic Prostatitis Cohort Study.","volume":"168","author":"Schaeffer","year":"2002","journal-title":"J Urol"},{"issue":"3","key":"jrv250024r45","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1097\/01.ju.0000082710.47402.03","article-title":"Pain sensitization in male chronic pelvic pain syndrome: why are symptoms so difficult to treat?","volume":"170","author":"Yang","year":"2003","journal-title":"J Urol"},{"issue":"4","key":"jrv250024r46","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.juro.2014.10.086","article-title":"Relationship between chronic nonurological associated somatic syndromes and symptom severity in urological chronic pelvic pain syndromes: baseline evaluation of the MAPP study.","volume":"193","author":"Krieger","year":"2015","journal-title":"J Urol"},{"issue":"5","key":"jrv250024r47","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.eururo.2012.10.042","article-title":"National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) symptom evaluation in multinational cohorts of patients with chronic prostatitis\/chronic pelvic pain syndrome.","volume":"63","author":"Wagenlehner","year":"2013","journal-title":"Eur Urol"},{"issue":"6","key":"jrv250024r48","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/S0090-4295(02)01963-5","article-title":"Symptoms and inflammation in chronic prostatitis\/chronic pelvic pain syndrome.","volume":"60","author":"Krieger","year":"2002","journal-title":"Urology"},{"issue":"4","key":"jrv250024r49","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s00345-013-1076-5","article-title":"Sexual dysfunction in chronic prostatitis\/chronic pelvic pain syndrome.","volume":"31","author":"Tran","year":"2013","journal-title":"World J Urol"},{"issue":"4","key":"jrv250024r50","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/j.juro.2008.06.032","article-title":"Mental health diagnoses in patients with interstitial cystitis\/painful bladder syndrome and chronic prostatitis\/chronic pelvic pain syndrome: a case\/control study.","volume":"180","author":"Clemens","year":"2008","journal-title":"J Urol"},{"issue":"2","key":"jrv250024r51","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S0022-5347(05)68562-X","article-title":"The National Institutes of Health Chronic Prostatitis Symptom Index: development and validation of a new outcome measure.","volume":"162","author":"Litwin","year":"1999","journal-title":"J Urol"},{"issue":"2","key":"jrv250024r52","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s11136-005-1317-1","article-title":"Responsiveness of the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI).","volume":"15","author":"Propert","year":"2006","journal-title":"Qual Life Res"},{"issue":"4","key":"jrv250024r53","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1097\/01.ju.0000054983.45096.16","article-title":"A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis.","volume":"169","author":"Nickel","year":"2003","journal-title":"J Urol"},{"issue":"2","key":"jrv250024r54","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.urology.2005.08.031","article-title":"Prostate-specific antigen test in diagnostic evaluation of chronic prostatitis\/chronic pelvic pain syndrome.","volume":"67","author":"Nadler","year":"2006","journal-title":"Urology"},{"issue":"11","key":"jrv250024r57","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1086\/375078","article-title":"Fluoroquinolone-associated tendinopathy: a critical review of the literature.","volume":"36","author":"Khaliq","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"5B","key":"jrv250024r60","doi-asserted-by":"publisher","first-page":"13S","DOI":"10.1016\/S0002-9343(99)00113-8","article-title":"Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications.","volume":"106","author":"Whelton","year":"1999","journal-title":"Am J Med"},{"issue":"8","key":"jrv250024r62","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1136\/bjophthalmol-2019-314765","article-title":"Association of macular disease with long-term use of pentosan polysulfate sodium: findings from a US cohort.","volume":"104","author":"Jain","year":"2020","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"jrv250024r64","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/S0090-4295(99)00358-1","article-title":"Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial.","volume":"54","author":"Shoskes","year":"1999","journal-title":"Urology"},{"issue":"3","key":"jrv250024r65","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.eururo.2009.05.046","article-title":"A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis\u2013chronic pelvic pain syndrome: a multicentre, randomised, prospective, double-blind, placebo-controlled phase 3 study.","volume":"56","author":"Wagenlehner","year":"2009","journal-title":"Eur Urol"},{"issue":"2","key":"jrv250024r66","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.juro.2007.09.088","article-title":"Muscle tenderness in men with chronic prostatitis\/chronic pelvic pain syndrome: the Chronic Prostatitis Cohort Study.","volume":"179","author":"Shoskes","year":"2008","journal-title":"J Urol"},{"issue":"6","key":"jrv250024r67","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.urology.2010.01.021","article-title":"Phenotypically directed multimodal therapy for chronic prostatitis\/chronic pelvic pain syndrome: a prospective study using UPOINT.","volume":"75","author":"Shoskes","year":"2010","journal-title":"Urology"},{"issue":"7","key":"jrv250024r68","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1111\/j.1464-410X.2012.11088.x","article-title":"a-Blockers, antibiotics and anti-inflammatories have a role in the management of chronic prostatitis\/chronic pelvic pain syndrome.","volume":"110","author":"Thakkinstian","year":"2012","journal-title":"BJU Int"},{"issue":"4","key":"jrv250024r69","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/bju.14988","article-title":"Pharmacological interventions for treating chronic prostatitis\/chronic pelvic pain syndrome: a Cochrane systematic review.","volume":"125","author":"Franco","year":"2020","journal-title":"BJU Int"},{"issue":"8","key":"jrv250024r70","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0041941","article-title":"Therapeutic intervention for chronic prostatitis\/chronic pelvic pain syndrome (CP\/CPPS): a systematic review and meta-analysis.","volume":"7","author":"Cohen","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"jrv250024r71","first-page":"1377","article-title":"Antibiotics are not beneficial in the management of category III prostatitis: a meta analysis.","volume":"11","author":"Zhu","year":"2014","journal-title":"Urol J"},{"issue":"4","key":"jrv250024r72","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1097\/01.ju.0000117811.40279.19","article-title":"Treatment of chronic prostatitis\/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial.","volume":"171","author":"Nickel","year":"2004","journal-title":"J Urol"},{"issue":"3","key":"jrv250024r73","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00345-010-0537-3","article-title":"Effects of a 6-month course of tamsulosin for chronic prostatitis\/chronic pelvic pain syndrome: a multicenter, randomized trial.","volume":"29","author":"Chen","year":"2011","journal-title":"World J Urol"},{"issue":"3","key":"jrv250024r74","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S0090-4295(03)00466-7","article-title":"Alfuzosin treatment for chronic prostatitis\/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled, pilot study.","volume":"62","author":"Mehik","year":"2003","journal-title":"Urology"},{"issue":"25","key":"jrv250024r75","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1056\/NEJMoa0803240","article-title":"Alfuzosin and symptoms of chronic prostatitis\u2013chronic pelvic pain syndrome.","volume":"359","author":"Nickel","year":"2008","journal-title":"N Engl J Med"},{"issue":"8","key":"jrv250024r76","doi-asserted-by":"publisher","first-page":"581","DOI":"10.7326\/0003-4819-141-8-200410190-00005","article-title":"Ciprofloxacin or tamsulosin in men with chronic prostatitis\/chronic pelvic pain syndrome: a randomized, double-blind trial.","volume":"141","author":"Alexander","year":"2004","journal-title":"Ann Intern Med"},{"issue":"2","key":"jrv250024r77","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1464-410X.2007.06667.x","article-title":"A prospective, randomized, double-blind trial to evaluate the role of a short reducing course of oral corticosteroid therapy in the treatment of chronic prostatitis\/chronic pelvic pain syndrome.","volume":"99","author":"Bates","year":"2007","journal-title":"BJU Int"},{"issue":"3","key":"jrv250024r78","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1258\/0956462053420239","article-title":"Treatment of category III A prostatitis with zafirlukast: a randomized controlled feasibility study.","volume":"16","author":"Goldmeier","year":"2005","journal-title":"Int J STD AIDS"},{"issue":"2","key":"jrv250024r79","doi-asserted-by":"publisher","first-page":"92","DOI":"10.5213\/inj.2011.15.2.92","article-title":"Tamsulosin monotherapy versus combination therapy with antibiotics or anti-inflammatory agents in the treatment of chronic pelvic pain syndrome.","volume":"15","author":"Kim","year":"2011","journal-title":"Int Neurourol J"},{"issue":"17","key":"jrv250024r80","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1001\/archinternmed.2010.319","article-title":"Pregabalin for the treatment of men with chronic prostatitis\/chronic pelvic pain syndrome: a randomized controlled trial.","volume":"170","author":"Pontari","year":"2010","journal-title":"Arch Intern Med"},{"issue":"3","key":"jrv250024r81","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ucl.2011.04.004","article-title":"Pollen extract for chronic prostatitis\u2013chronic pelvic pain syndrome.","volume":"38","author":"Wagenlehner","year":"2011","journal-title":"Urol Clin North Am"},{"issue":"4","key":"jrv250024r82","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1097\/01.ju.0000159198.83103.01","article-title":"Pentosan polysulfate sodium therapy for men with chronic pelvic pain syndrome: a multicenter, randomized, placebo controlled study.","volume":"173","author":"Nickel","year":"2005","journal-title":"J Urol"},{"issue":"1","key":"jrv250024r83","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/JU.0000000000002756","article-title":"Diagnosis and treatment of interstitial cystitis\/bladder pain syndrome.","volume":"208","author":"Clemens","year":"2022","journal-title":"J Urol"},{"key":"jrv250024r1","first-page":"335","volume-title":"Male Lower Urinary Tract Symptoms (LUTS): An International Consultation on Male LUTS","author":"Nickel","year":"2012"},{"key":"jrv250024r55","unstructured":"US Food and Drug Administration. Ciprofloxacin (Cipro) highlights of prescribing information. Accessed June 28, 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/019537s095,020780s050lbl.pdf"},{"key":"jrv250024r56","unstructured":"US Food and Drug Administration. Levofloxacin (Levaquin) highlights of prescribing information. Accessed June 28, 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/020634s069lbl.pdf"},{"key":"jrv250024r58","unstructured":"Food and Drug Administration. Flomax (tamsulosin) highlights of prescribing information. Accessed June 26, 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/020579s033lbl.pdf"},{"key":"jrv250024r59","unstructured":"Food and Drug Administration. Uroxatral (alfuzosin) highlights of prescribing information. Accessed June 26, 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/021287s024lbl.pdf"},{"key":"jrv250024r61","unstructured":"US Food and Drug Administration. Lyrica (pregabalin) highlights of prescribing information. Accessed June 28, 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/021446s046,022488s022lbl.pdf"},{"key":"jrv250024r63","unstructured":"US Food and Drug Administration. Elmiron (pentosan polysulfate sodium) prescribing information. Accessed June 28, 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/020193s015lbl.pdf"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2837543\/jama_borgert_2025_rv_250024_1757361734.35259.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T15:00:45Z","timestamp":1758034845000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2837543"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2025,9,16]]},"references-count":83,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,9,16]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2025.11499","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,16]]}}}